Heparanase is essential for the development of diabetic nephropathy in mice

Diabetes

Volumn 61, Issue 1, 2012, Pages 208-216

  Gil, Natali ^a   Goldberg, Rachel ^a   Neuman, Tzahi ^a   Garsen, Marjolein ^b   Zcharia, Eyal ^c   Rubinstein, Ariel M ^a   Van Kuppevelt, Toin ^b   Meirovitz, Amichay ^a   Pisano, Claudio ^d   Li, Jin Ping ^e   Van Der Vlag, Johan ^b   Vlodavsky, Israel ^c   Elkin, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Sigma Tau SpA   (Italy)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; ENZYME INHIBITOR; HEPARANASE; SST 0001; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME INDUCTION; GENE DELETION; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION;

ANIMALS; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GLUCURONIDASE; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; STREPTOZOCIN;

EID: 84555188487     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1024     Document Type: Article

References (50)

1. Ibrahim HN, Hostetter TH. Diabetic nephropathy. J Am Soc Nephrol 1997; 8:487-493 (Pubitemid 127454185)
2. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005;16:3736-3741 (Pubitemid 46211296)
3. Atkins RC, Zimmet P; World Kidney Day Steering Committee. Diabetic kidney disease: act now or pay later. J Am Soc Hypertens 2010;4:3-6
4. Szymczak M, Kuźniar J, Klinger M. The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp (Warsz) 2010;58:45-56
5. van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, van der Vlag J. Heparanase in glomerular diseases. Kidney Int 2007;72:543-548 (Pubitemid 47312787)
6. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med 2007;11:427-452 (Pubitemid 47153456)
7. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-M108 (Pubitemid 32206686)
8. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802 (Pubitemid 29318614)
9. Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 2001;108:165-167 (Pubitemid 32656237)
10. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001;15:1661-1663
11. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998;4:691-697 (Pubitemid 28274669)
12. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009;102:823-828
13. Katz A, Van-Dijk DJ, Aingorn H, et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 2002;4:996-1002
14. van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006;70:2100-2108 (Pubitemid 44871372)
15. Levidiotis V, Freeman C, Punler M, et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol 2004; 15:2882-2892 (Pubitemid 41103397)
16. Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005;54:2172-2178 (Pubitemid 40911281)
17. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev 2001;17:412-421 (Pubitemid 34030743)
18. Miner JH. Renal basement membrane components. Kidney Int 1999;56: 2016-2024 (Pubitemid 30004730)
19. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000;57:385-400 (Pubitemid 30430630)
20. van den Born J, Pisa B, Bakker MA, et al. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy. J Biol Chem 2006;281:29606-29613 (Pubitemid 44536968)
21. Harvey SJ, Miner JH. Revisiting the glomerular charge barrier in the molecular era. Curr Opin Nephrol Hypertens 2008;17:393-398
22. Zcharia E, Jia J, Zhang X, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 2009;4:e5181
23. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005;280:12103-12113
24. Ritchie JP, Ramani VC, Ren Y, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 2011;17:1382-1393
25. Qi Z, Fujita H, Jin J, et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005;54:2628-2637 (Pubitemid 41233584)
26. Lerner I, Hermano E, Zcharia E, et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 2011;121:1709-1721
27. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 1998;273:12960-12966 (Pubitemid 28246857)
28. Doviner V, Maly B, Kaplan V, et al. Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 2006;19:878-888 (Pubitemid 43780459)
29. Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003; 63:8749-8756 (Pubitemid 38064053)
30. Cohen I, Maly B, Simon I, et al. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13:4069-4077 (Pubitemid 47105967)
31. de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, Hulett MD. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 2005;280:35136-35147 (Pubitemid 41532700)
32. Breyer MD, Böttinger E, Brosius FC 3rd, et al.; AMDCC. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005;16:27-45 (Pubitemid 43073154)
33. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627-1637 (Pubitemid 29518163)
34. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004;15(Suppl. 1):S55-S57 (Pubitemid 38018457)
35. Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-b activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 2011;178:2573-2586
36. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993;90:1814-1818 (Pubitemid 23069947)
37. Tesch GH. Macrophages and diabetic nephropathy. Semin Nephrol 2010; 30:290-301
38. Tuttle KR. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 2005;16:1537-1538 (Pubitemid 41716459)
39. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006;11:226-231 (Pubitemid 43829442)
40. Starkey PM, Turley L, Gordon S. The mouse macrophage-specific glycoprotein defined by monoclonal antibody F4/80: characterization, biosynthesis and demonstration of a rat analogue. Immunology 1987;60:117-122 (Pubitemid 17230149)
41. Ogishima T, Shiina H, Breault JE, et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 2005;11:1028-1036 (Pubitemid 40175750)
42. de Mestre AM, Staykova MA, Hornby JR, Willenborg DO, Hulett MD. Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J Leukoc Biol 2007;82:1289-1300 (Pubitemid 350133527)
43. Hasan RN, Phukan S, Harada S. Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:988-993 (Pubitemid 36713550)
44. Elkin M, Cohen I, Zcharia E, et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 2003;63:8821-8826 (Pubitemid 38064061)
45. Casu B, Vlodavsky I, Sanderson RD. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 2008;36:195-203
46. Yang Y, MacLeod V, Dai Y, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007;110:2041-2048 (Pubitemid 47443921)
47. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. Curr Diab Rep 2004;4:435-440 (Pubitemid 40104219)
48. Josefsen K, Sørensen LR, Buschard K, Birkenbach M. Glucose induces early growth response gene (Egr-1) expression in pancreatic beta cells. Diabetologia 1999;42:195-203 (Pubitemid 29064242)
49. Meirovitz A, Hermano E, Lerner I, et al. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 2011;71:2772-2780
50. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433-442 (Pubitemid 351355386)